Ongoing studies for margetuximab32, pyrotinib33, trastuzumab deruxtecan34, ARX78835, and PRS-34336 may expand upon or improve current options for patients with HER2-positive breast cancer, and illuminate the impact of additional HER2-targeted agents on IMD incidence. This evidence concerns the gene ERBB2 and breast cancer.